Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 4 of these applications claim priority to application 16/877,069, filed May 18, 2020. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,207,349 | Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof In force · High confidence | Abelzeta Inc. | In force | High confidence | ||
| US 11,439,665 | Combined Chimeric Antigen Receptor Targeting CD19 and CD20 and Application Thereof In force · High confidence | Abelzeta Inc. | In force | High confidence | ||
| US 11,633,430 | Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof In force · High confidence | Abelzeta Inc. | In force | High confidence | ||
| US 12,448,432 | Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof In force · High confidence | Abelzeta Inc. | In force | High confidence | ||
| US 12,753,221 | Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof In force · High confidence | Abelzeta Inc. | In force | High confidence | ||
| Application 17/911,502 | Combined Chimeric Antigen Receptor Targeting CD19 and CD20 and Application Thereof Pending Not granted | Abelzeta Inc. | Pending | Not granted | ||
| Application 17/911,524 | Combined Chimeric Antigen Receptor Targeting CD19 and CD20 and Applications Thereof Abandoned Abandoned Aug 22, 2026 | Abelzeta Inc. | Abandoned | Abandoned Aug 22, 2026 |
7 of 7 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
5 of these are in force and held by Abelzeta Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.